Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2021-02-19 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of FDA approval for marketing generic Droxidopa Capsules. It contains no financial statements, no detailed financial data, no regulatory certifications, or voting results. It is a corporate announcement about product approval, not a financial report or regulatory filing. The document length is short (3135 characters) and it is clearly a press release. This type of document does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is an announcement related to corporate operations and product approval, which is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2021-02-19 English
Lupin Receives Approval for Droxidopa Capsules.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for Lupin Limited's Droxidopa Capsules. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content focuses on the approval news and product details, not on financial results or detailed reports. The document length is 4219 characters, relatively short, and it is a disclosure announcement rather than a detailed report or financial filing. There is no indication of financial statements, management discussion, or regulatory certifications. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and disclosure under SEBI regulations.
2021-02-19 English
Lupin Launches Posaconazole Delayed-Release Tablets.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Posaconazole Delayed-Release Tablets) by Lupin Limited following FDA approval of its ANDA by its alliance partner. It is addressed to stock exchanges and references disclosure requirements under SEBI regulations. The content is a corporate announcement about a product launch and regulatory approval, not a financial report, earnings release, or management discussion. The document length is 4292 characters, which is relatively short and typical for a press release. There is no financial data, no detailed report, no voting results, no management changes, no legal proceedings, or other specific report content. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other categories.
2021-02-17 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Posaconazole Delayed-Release Tablets) by Lupin Limited. It contains no financial data, no regulatory filing references, no voting results, no management or board changes, no earnings or interim report data, and no detailed investor presentation. The document is short (3180 characters) and serves as a corporate announcement about a product launch. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-02-17 English
Allotment of Securities
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no textual content or financial information. It is extremely short (169 characters) and does not contain any report, announcement, or regulatory information. Given the lack of content, the document cannot be classified as a substantive report or announcement. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings without clear classification.
2021-02-12 English
Disclosure in respect of allotment of 3583 shares under ESOP.
Share Issue/Capital Change Classification · 100% confidence The document is a letter addressed to BSE Limited disclosing the allotment of shares under the Employee Stock Option Plan (ESOP). It mentions the allotment of fully paid-up equity shares and the resulting increase in the company's issued and paid-up capital. The document is short (1249 characters) and is an announcement of a capital change due to share allotment. It does not contain financial statements or detailed financial analysis, nor is it a report or presentation. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2021-02-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.